INT239373

Context Info Confidence 0.25 First Reported 2008 Last Reported 2011 Negated 0 Speculated 1 Reported most in Body Documents 3 Total Number 4 Disease Relevance 4.98 Pain Relevance 0.12

lipid binding (PTEN) cell proliferation (PTEN) cytosol (PTEN) plasma membrane (PTEN) nucleus (PTEN) enzyme binding (PTEN)

Anatomy Link Frequency cleavage 2 PTEN (Homo sapiens)

Pain Link Frequency Relevance Heat agonist 21 95.44 cva 3 25.76 Inflammation 3 24.60 Central nervous system 22 5.00 Bioavailability 3 5.00 Pain 3 5.00 Angina 2 5.00 qutenza 2 5.00 addiction 2 5.00 pruritus 2 5.00

Disease Link Frequency Relevance Heat Lung Cancer 11 99.40 Basal And Squamous Cell Skin Cancer 71 99.00 Apoptosis 20 98.80 Cancer 209 98.68 Papillomavirus Infection 55 97.60 Lichen Sclerosus Et Atrophicus 32 91.80 Carcinoma 3 89.76 Malignant Neoplastic Disease 8 84.64 Advanced Or Metastatic Breast Cancer 28 80.92 Microsatellite Instability 6 76.64

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

of IkB, induction of TSC22, NF-kB, GADD153, PTEN, etc.) may depend on the

Spec (may) Positive_regulation (depend) of Positive_regulation (induction) of PTEN

1) Confidence 0.25 Published 2008 Journal PPAR Research Section Body Doc Link PMC2464819 Disease Relevance 0.80 Pain Relevance 0

TZDs induced upregulation of PTEN and p21, downregulation of cyclins D and E, and

Positive_regulation (induced) of Positive_regulation (upregulation) of PTEN

2) Confidence 0.19 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528242 Disease Relevance 1.38 Pain Relevance 0.12

Somatic mutation of PTEN was also demonstrated in some cases of vulvar SCC and VIN, suggesting that PTEN mutation possibly played a role early in the carcinogenesis of vulvar SCC [37].

Positive_regulation (demonstrated) of Positive_regulation (mutation) of PTEN associated with cancer and basal and squamous cell skin cancer

3) Confidence 0.18 Published 2011 Journal Journal of Skin Cancer Section Body Doc Link PMC3003991 Disease Relevance 2.54 Pain Relevance 0

Despite documented HER2 receptor amplification, patients may have de novo or acquired resistance to trastuzumab. 39 Potential mechanisms of trastuzumab resistance include altered receptor–antibody interaction (MUC4, p95HER2, ErbB2 mutations), altered downstream signaling (reduced p27, reduced PTEN, activation of PI3K, activation of Akt) and crosstalk with other signaling pathways (IGF-R1, ER, VEGFR).40 The p95HER2 receptor is created either by cleavage and shedding of the extracellular domain of the HER2 receptor or by specific mRNA splicing, resulting in a constitutively active truncated receptor which is associated with a more aggressive phenotype.

Positive_regulation (activation) of Positive_regulation (activation) of PTEN in cleavage

4) Confidence 0.12 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.26 Pain Relevance 0

General Comments

This test has worked.